Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PTC Therapeutics's enterprise value is €3,674.6 Mil.
PTC Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €151.1 Mil. Therefore, PTC Therapeutics's EV-to-EBITDA for today is 24.32.
The historical rank and industry rank for PTC Therapeutics's EV-to-EBITDA or its related term are showing as below:
FRA:BH3'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -254.46 Med: -9.86 Max: 36.17
Current: 24.75
During the past 13 years, the highest EV-to-EBITDA of PTC Therapeutics was 36.17. The lowest was -254.46. And the median was -9.86.
FRA:BH3's EV-to-EBITDA is ranked worse than 66.18% of 408
companies
in the Biotechnology industry
Industry Median: 14.13
vs FRA:BH3: 24.75
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PTC Therapeutics's PE Ratio (TTM) for today is calculated as:
PTC Therapeutics's share price for today is €59.44.
PTC Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.483.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for PTC Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BH3 vs XENE, CGON, ERAS: EV-to-EBITDA Comparison
For the Biotechnology subindustry, PTC Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's EV-to-EBITDA falls into.
PTC Therapeutics's current Enterprise Value is €3,674.6 Mil.
PTC Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €151.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTC Therapeutics (FRA:BH3) has a EV-to-EBITDA of 24.32 as of Aug. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PTC Therapeutics. According to the industry distribution chart, PTC Therapeutics ranks #270 out of 408 companies in the Biotechnology industry, placing it in the top 66.2%.
Is PTC Therapeutics' EV-to-EBITDA too high?
PTC Therapeutics' current EV-to-EBITDA is 24.32. The Biotechnology industry median EV-to-EBITDA is 14.13. PTC Therapeutics' value of 24.32 is 72.1% above this industry median. Based on the distribution chart, PTC Therapeutics ranks #270 out of 408 companies in the Biotechnology industry, which is below the industry midpoint. Overall, PTC Therapeutics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' EV-to-EBITDA compare to XENE and CGON?
According to the Biotechnology industry distribution chart, PTC Therapeutics ranks #270 out of 408 companies for EV-to-EBITDA. This places PTC Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 14.13. PTC Therapeutics' value of 24.32 is 72.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.13, based on 408 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PTC Therapeutics's current EV-to-EBITDA of 24.32 is 72.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PTC Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 14.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PTC Therapeutics's current EV-to-EBITDA is 24.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
PTC Therapeutics (FRA:BH3) has a current EV-to-EBITDA of 24.32. The stock's GF Value™ is €32.19, compared to a current price of €59.44 — trading 84.7% above its estimated fair value. The current EV-to-EBITDA is 24.32 and 72.1% above the Biotechnology industry median of 14.13. PTC Therapeutics' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PTC Therapeutics (FRA:BH3), the current EV-to-EBITDA is 24.32 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?
Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued.
The current stock price of €59.44 is trading 84.7% above its estimated GF Value™ of €32.19.
Key valuation signals for FRA:BH3:
EV-to-EBITDA: 24.32
GF Value™: €32.19 vs. price of €59.44 (84.7% above fair value)
Industry Position: 72.1% above the Biotechnology median (#270 of 408)
No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
51GF Score
Get the complete analysis for FRA:BH3
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BH3 has been successfully added to your 
